Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE
2025-520535-16-00Phase 4Authorised
- Sponsor
- Parc de Salut Mar
- Start
- Jul 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in end-stage kidney disease (ESKD) (2 arms), sponsored by Parc de Salut Mar. Primary endpoint: Composite outcome of patient survival with functioning graft at 12 months. Planned start Jul 2025; status: authorised.
02
Drugs
tacrolimus
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2025-520535-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520535-16-00.